{"product_id":"global-mrna-cancer-vaccines-and-therapeutics-market-growth-status-and-outlook-2023-2029","title":"Global mRNA Cancer Vaccines and Therapeutics Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal mRNA Cancer Vaccines and Therapeutics Market Growth (Status and Outlook) 2023-2029\u003c\/p\u003e\n\n\u003cp\u003emRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “mRNA Cancer Vaccines and Therapeutics Industry Forecast” looks at past sales and reviews total world mRNA Cancer Vaccines and Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected mRNA Cancer Vaccines and Therapeutics sales for 2023 through 2029. With mRNA Cancer Vaccines and Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Cancer Vaccines and Therapeutics industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global mRNA Cancer Vaccines and Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on mRNA Cancer Vaccines and Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global mRNA Cancer Vaccines and Therapeutics market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Cancer Vaccines and Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Cancer Vaccines and Therapeutics.\u003c\/p\u003e\n\n\u003cp\u003eThe global mRNA Cancer Vaccines and Therapeutics market size is projected to grow from US$ 137.3 million in 2022 to US$ 483.9 million in 2029; it is expected to grow at a CAGR of 19.7% from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eNorth America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.\u003c\/p\u003e\n\n\u003cp\u003eThe key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of mRNA Cancer Vaccines and Therapeutics market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nAdeno Carcinomas\u003cbr\u003e\nMucinous Carcinomas\u003cbr\u003e\nAdenosquamous Carcinomas\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nInfectious Disease\u003cbr\u003e\nCancer\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\n United States\u003cbr\u003e\n Canada\u003cbr\u003e\n Mexico\u003cbr\u003e\n Brazil\u003cbr\u003e\nAPAC\u003cbr\u003e\n China\u003cbr\u003e\n Japan\u003cbr\u003e\n Korea\u003cbr\u003e\n Southeast Asia\u003cbr\u003e\n India\u003cbr\u003e\n Australia\u003cbr\u003e\nEurope\u003cbr\u003e\n Germany\u003cbr\u003e\n France\u003cbr\u003e\n UK\u003cbr\u003e\n Italy\u003cbr\u003e\n Russia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\n Egypt\u003cbr\u003e\n South Africa\u003cbr\u003e\n Israel\u003cbr\u003e\n Turkey\u003cbr\u003e\n GCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nModerna Therapeutics\u003cbr\u003e\nCureVac\u003cbr\u003e\nTranslate Bio\u003cbr\u003e\nBioNTech\u003cbr\u003e\nSangamo Therapeutics\u003cbr\u003e\nArgos Therapeutics\u003cbr\u003e\nIn-Cell-Art\u003cbr\u003e\neTheRNA\u003cbr\u003e\nEthris\u003cbr\u003e\nTiba Biotechnology\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 102 Pages \/ MCW16226240","offer_id":47640125669682,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-mrna-cancer-vaccines-and-therapeutics-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}